Dr Geoffrey Nichol, Sangamo BioSciences, USA

Dr Geoffrey Nichol

Geoff Nichol BMed Sc, MB, ChB, MBA, FRACP is currently Executive Vice President of Research and Development at Sangamo BioSciences in San Francisco, USA.  He has over 20 years of experience in the pharmaceutical and biotechnology industries, and has been closely associated with the development of over 15 new drug candidates and the approval or launch of several marketed drugs, including Augmentin BID (amoxicillin/clavulanate), Foradil (formoterol) and Yervoy (ipilimumab). He started his career in drug development with SmithKline Beecham, then served on the senior global development management team at Novartis. He then led all aspects of product development for Medarex Inc, pioneering the pharmaceutical development of the novel immunotherapeutic antibodies ipilimumab, the first agent to improve survival in advanced melanoma, and nivolumab. Following the acquisition of Medarex by Bristol-Myers Squibb Company in 2009, he served as CMO at Ikaria prior to joining Sangamo.

« Go Back

Supporting Publication
Organised by
  • Lancet Neurology
  • Elsevier
Silver Sponsor